1

1
2

Crohn
1/-

4
2

 Crohn

( )

,
: 20-30 60-70

Bowel rest


Anti-TNF
Infliximab
Adalimumab
Certolizumab pegol

Anti-integrin 4
Vedolizumab
Natalizumab

Infliximab
EMA approval: 1999
mAb IgG1 -

:
Crohn


:
,
,
:
, , ,
, ,

Adalimumab

EMA approval: 2003

mAb IgG1

TNF

:
Crohn


:
infliximab

:
, ,
, -, ,
,

Certolizumab pegol
FDA approval: 2008

- (Kawalek et al, 2013)

The role of
selected integrins
in lymphocyte
migration

Natalizumab
FDA approval: 2008
-4

PML (JC virus) EMA

MS

Vedolizumab
EMA approval: 2014
mAb IgG1
-47



:
Crohn,

anti-TNF ( )


:
,
:
, ,

CD + UC = IBD

anti-TNF anti-integrin 4
nti-TNF: infliximab, adalimumab
Anti-integrin 4: vedolizumab